



Mar 26, 2021

HIV-1 Genotyping and Drug Resistance by Next Generation Sequencing

Brenna M McGruder Rawson¹, Matthew Schimenti¹, Jason Blanton¹¹Florida Department of Health, Bureau of Public Health Laboratories

In Development

dx.doi.org/10.17504/protocols.io.btpqnmw

Jason Blanton

SUBMIT TO PLOS ONE

ABSTRACT

The Florida Department of Health's Bureau of Public Health Laboratories in Jacksonville is developing a protocol for the Next Generation Sequencing (NGS) of HIV, primarily for the purpose of drug-resistant mutation identification. This HIV-1 protocol uses amplicon based sequencing. The amplified *pol* gene regions are used in both genotyping and drug resistance determination. The NGS data generated can also be used in surveillance and outbreak monitoring, giving epidemiologist more information about circulating viral genomes.

The imminent sunset of ViroSeq (Abbott Molecular) has required many labs to look for new methods to continue identifying HIV-1 drug resistance strains for both clinical management and epidemiological study. NGS was chosen as it is more cost effective than investing in a single pathogen platform. NGS allows for one sample to produce results and data that can aid not just a patient but an entire population.

DOI

dx.doi.org/10.17504/protocols.io.btpqnmw

PROTOCOL CITATION

Brenna M McGruder Rawson, Matthew Schimenti, Jason Blanton 2021. HIV-1 Genotyping and Drug Resistance by Next Generation Sequencing. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.btpqnmw>



MANUSCRIPT CITATION please remember to cite the following publication along with this protocol

KEYWORDS

HIV-1, HIV-1 genotyping, HIV-1 drug resistance, Next Generation sequencing, drug resistance mutations

LICENSE

———— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Mar 26, 2021

LAST MODIFIED

Mar 26, 2021

PROTOCOL INTEGER ID

48592

MATERIALS TEXT

QIAamp DSP Viral RNA Mini Kit DSP or RUO (Qiagen, Germantown, MD)

Invitrogen SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity DNA Polymerase (cat 12574-035)

Primers FL_HIV-1 *Ext Nest FW* and FL_HIV-1 *Ext Nest RV* designed in house

Primers HIV2522-F and HIV5073-R designed by Dudley et al.

A	B	C
FL_HIV-1_Ext Nest FW	GAC TTC CCT CAR ATC ACT CTT TGGC	10µM
FL_HIV-1_Ext Nest RV	TGC CAC ACA ATC ATC ACC TGC C	10µM
HIV2252-F	CCC TCA RAT CAC TCT TTG GC	10µM
HIV5073-R	CCA CAC AAT CAT CAC CTG CC	10µM

Primers for HIV-1 Genotyping by Next Generation Sequencing

Single/multichannel pipettes with p20/p200/p1000 tips

Thermocycler

Nuclease-free water

Dimethyl Sulfoxide, biology grade

AMPure XP Beads (Beckman Coulter)

Magnetic stand

Tapestation or Agarose gel

Qubit or other quantitation method

Illumina Nextera XT DNA Library Prep Kit

Illumina Nextera v2 Index Kits

Illumina iSeq

Illumina iSeq 100 i1 v2 cartridge

<https://www.smartgene.com/>

DISCLAIMER:

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to [protocols.io](https://www.protocols.io) is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with [protocols.io](https://www.protocols.io), can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

The use of reagents, equipment, or services in this protocol is not an endorsement either stated or implied by the Florida Department of Health.







RNA Extraction













1 Extract RNA using the Qiagen Viral RNA Mini Kit (DSP or RUO)

1.1 Add 5.6 µl carrier RNA/ sample

1.2 Follow Kit Instructions







Reverse-Transcription and Amplification










- 2 Master Mix with Invitrogen SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity DNA Polymerase (cat 12574-035)
 -  **25 µl 2x Reaction Mix**
 -  **1.0 µl HIV2252-F**
 -  **1.0 µl HIV5073-R**
 -  **1.0 µl SuperScript III Platinum Taq**
 -  **2.5 µl DMSO**
 -  **19.5 µl viral RNA template**

- 3 Reverse-Transcription/Amplification PCR thermocycler settings 38m 45s
 -  **105 °C Lid setting**
 -  **50 °C**  **00:30:00**
 - 15 cycles
 -  **94 °C**  **00:00:15**
 -  **55 °C**  **00:00:30**
 -  **68 °C**  **00:03:00**
 - Final extension
 -  **78 °C**  **00:05:00**
 -  **4 °C Hold**

- 4 Using a ratio of 0.5 follow the AMPure XP bead protocol for PCR purification

Second Amplification

- 5 Master Mix with Invitrogen SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity DNA Polymerase (cat 12574-035)
 -  **25 µl 2x Reaction Mix**
 -  **1.0 µl FL_HIV_Ext Nest FW**
 -  **1.0 µl FL_HIV_Ext Nest RV**
 -  **1.0 µl SuperScript III Platinum Taq**
 -  **2.5 µl DMSO**
 -  **19.5 µl clean cDNA template**

- 6 Second Amplification PCR thermocycler settings 8m 45s
 -  **105 °C Lid setting**
 - 40 cycles
 -  **94 °C**  **00:00:15**
 -  **55 °C**  **00:00:30**
 -  **68 °C**  **00:03:00**
 - Final extension
 -  **78 °C**  **00:05:00**

4 °C Hold


7 Using a ratio of 0.5 follow the AMPure XP bead protocol for PCR purification

8 Visualize samples using Tapestation or agarose gel

8.1 Fragments should be ~2.9 kb

8.2 If the 2.9 kb fragment is isolated then samples should sequence well. If there are additional fragments sequencing is still possible, but samples may require a higher input concentration to achieve desired coverage

Library Preparation

9 Quantitate Samples and dilute as needed to achieve  1.0 ng input concentration per sample

10 Follow Illumina Protocol for Nextera XT DNA Library Sample Prep

Pooling Samples

11 Amplicon quality can effect how many samples can be pooled onto one run. Use caution in deciding how many samples to pool.

11.1 Normalize samples prior to pooling by dilution

11.2 Samples should be pooled in an equal volume amount. If desired the pool can be cleaned using an additional AMPure XP bead clean.

11.3 Quantitate the Pooled Library

12 Dilute the Pooled Library to apx. 0.07 ng/μL or a concentration found in the Illumina iSeq manual

13 Add  5 µl [M] 1 Nanomolar (nM) PhiX to the pool

14 Load according to Illumina instructions

Analysis

15 We currently use SmartGene HIV-1 pipeline (<https://www.smartgene.com/>) for analysis

Pipeline Name: HIV-1 PR+RT+IN

Version 2.2.0 *HIV1* V1.6

Noise Filter [%] 0.5

Interpretation cut off [%] 5.0

Minimum read depth and additional criteria should be determined by your institution

References

16 Dudley DM, Bailey AL, Mehta SH, Hughes AL, Kirk GD, Westergaard RP, O'Connor DH. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq. *Retrovirology*. 2014 Dec 23;11:122. doi: 10.1186/s12977-014-0122-8. PMID: 25533166; PMCID: PMC4302432.